my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
10-07-2009: Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton’s Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acquires the exclusive right to market and distribute insulin produced by Bioton under the trade name of SciLin® in China. The contract and payment guarantee the exclusive commercial delivery of this recombinant insulin to Bayer in China with a secured supply of the product for the next 15 years.
“Through the planned distribution of SciLin®, we will further supply patients suffering from diabetes, and will expand our position in this very promising growth market,” said Andreas Fibig, CEO of Bayer Schering Pharma AG.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Bayer to acquire Conceptus, Inc.
Bayer intends to broaden its portfolio in the field of contraception. Thus, Bayer HealthCare LLC has signed a merger agreement with Conceptus, Inc. (CPTS), the California, U.S., based developer of the Essure® procedure, the leading non-surgical permanent birth control method, which is sold ... more
New products create optimism for the future
2012 was a very successful year for the Bayer Group. “We continued to grow dynamically and achieved our targets for the Group. All the subgroups posted gains in sales and earnings before special items,” said Bayer CEO Dr. Marijn Dekkers at the Financial News Conference in Leverkusen on Thur ... more
Humboldt Foundation cooperates with Bayer Foundation
The Alexander von Humboldt Foundation and the Bayer Science & Education Foundation will soon be awarding joint research fellowships. Until 2018, the Bayer Foundation will be making around three million EUR available to fund approximately ten Humboldt-Bayer Research Fellowships annually. The ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Pharmaceuticals Corporation
Outstanding specialty care takes constant innovation and dedication. These core values set Bayer HealthCare Pharmaceuticals apart and enable us to offer an industry-leading portfolio of products and support that healthcare providers and their patients require. Bayer HealthCare Pharmaceutic ... more
Bayer Schering GmbH, Leverkusen (formerly Dritte BV GmbH) today informed the Management Board of Schering AG that the cash compensation for the requested transfer of the shares of Schering’s minority shareholders (squeeze-out) has been determined as EUR 98.98 per Schering share. The amount ... more
Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more
Bayer acquires exclusive rights to Bioton’s insulin SciLin
Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton’s Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acqui ... more
Biopartners Appoints Dr Conrad Savoy as CEO
Biopartners GmbH has announced the appointment of Dr Conrad Savoy as its new CEO and President of the Board from the 1st of May 2009. The change, which sees former CEO, Jean-Noël Treilles remain closely involved with the company in advisory consultancy role, is the result of a planned succe ... more
Biopartners Holdings AG Purchased by Bioton S.A.
Biopartners Holdings AG has announced that it has been purchased in a deal worth $78M by Bioton S.A., a Polish biotechnology company. Bioton S.A., and entities associated with DLJ Merchant Banking Partners signed a purchase agreement for 100% shares in share capital on 9th March 2007, inclu ... more
Headquartered in Warsaw, Poland, a Warsaw Stock Exchange listed company, Bioton S.A. is among the first four companies worldwide being able to produce recombinant human insulin. This product is already registered on the most attractive markets. Bioton is able to pursue its strategic objec ... more
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ... more
Bayer launches Betaferon in China
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Bayer acquires exclusive rights to Bioton’s insulin SciLin
Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton’s Singaporean subsidiary, SciGen, to strengthen its pharmaceutical product portfolio. For an up-front payment of 31 million Euros, Bayer acqui ... more
NasVax Ltd. announced that it has entered into a partnership agreement with SciGen Ltd. to develop and market a vaccine administered through the intranasal route for preventing Hepatitis B disease. This development product combines SciGen's Hepatitis B antigen with NasVax's VaxiSomeTM that ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
